E10.3529 Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye

Name of the Condition

Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye

Summary

Type 1 diabetes mellitus is an autoimmune condition characterized by insufficient insulin production. When complicated by proliferative diabetic retinopathy with traction retinal detachment involving the macula, abnormal blood vessel growth occurs on the retina, leading to fibrous tissue formation that pulls the retina away from its underlying layers. This detachment specifically involves the macula, the central part of the retina responsible for sharp vision, increasing the risk of severe and permanent vision loss if not addressed promptly. The unspecified eye designation indicates the condition affects either eye without specifying which one.

Causes

Type 1 diabetes results from an autoimmune response targeting insulin-producing pancreatic cells. Proliferative diabetic retinopathy with traction retinal detachment develops due to prolonged hyperglycemia, which damages retinal blood vessels and triggers abnormal vessel growth. The underlying diabetes drives the retinal changes, including the formation of fibrous scar tissue that exerts traction on the retina, leading to detachment. The unspecified eye designation reflects the lack of documentation specifying a particular eye.

Risk Factors

• Long duration of diabetes.
• Poor glycemic control.
• Hypertension.
• Dyslipidemia.
• Smoking.

Symptoms

• Sudden or progressive vision loss.
• Blurry or distorted central vision.
• Floaters or dark spots in the visual field.
• Visual field defects.

Diagnosis

Diagnosis involves a comprehensive eye examination, including dilated retinal imaging (e.g., fundus photography, optical coherence tomography) to assess retinal detachment and macular involvement. Fluorescein angiography may be used to evaluate abnormal blood vessel growth. Medical history, including diabetes duration and glycemic control, is reviewed. The unspecified eye designation is confirmed if documentation does not specify a particular eye.

Treatment Options

Treatment focuses on stabilizing the retina and preserving vision. Options may include laser photocoagulation to reduce abnormal vessel growth, vitrectomy surgery to remove fibrous tissue and reattach the retina, and intraocular medications to inhibit vessel proliferation. Glycemic control and blood pressure management are critical adjuncts. The unspecified eye designation guides treatment planning for either eye.

Prognosis and Follow-Up

Prognosis depends on the extent of macular detachment and timely intervention. Early treatment improves outcomes, but severe detachment may result in permanent vision loss. Regular follow-up with an ophthalmologist is essential to monitor retinal status and adjust treatment. Glycemic control and risk factor management are ongoing priorities.

Complications

• Permanent vision loss or blindness.
• Recurrent retinal detachment.
• Glaucoma.
• Cataracts.

Lifestyle & Prevention

• Maintain strict glycemic control to slow retinal damage.
• Regular eye examinations to detect early changes.
• Manage blood pressure and cholesterol levels.
• Avoid smoking to reduce vascular risk.
• Promptly address any vision changes.

When to Seek Professional Help

Seek immediate medical attention for sudden vision loss, floaters, or distorted vision. Regular ophthalmologic evaluations are recommended for individuals with Type 1 diabetes, especially those with a history of retinopathy.

Tips for Medical Coders

Document the unspecified eye designation clearly if the eye is not specified. Ensure supporting documentation confirms proliferative diabetic retinopathy with traction retinal detachment involving the macula. The code E10.3529 is used when the eye is not documented as right or left.